![](https://www.medicinesforeurope.com/wp-content/uploads/2016/03/twitter.png)
![](https://www.medicinesforeurope.com/wp-content/uploads/2016/03/Logo_LinkedIn_round.png)
![](https://www.medicinesforeurope.com/wp-content/uploads/2016/03/youtube.png)
![](https://www.medicinesforeurope.com/wp-content/uploads/2016/03/flickr.png)
It was with great pleasure that the Value Added Medicines Group, sector group of Medicines for Europe, participated in a panel at ISPOR 20th Annual European Congress (Glasgow, Scotland; 6 November), entitled Value Added Medicines: Time To Adjust The Health Technology Assessment Decision Frameworks?. This panel counted on notable speakers – Pr. Michael Drummond, Pr. Toumi, Pr. Ulf Persson and the chairman of the value added medicines sector group, Umberto Comberiati – who highlighted us on the current challenges and key recommendations to integrate patient-centric innovation in the HTA decision frameworks in Europe. Please check out some nice photos of the event:
https://twitter.com/medicinesforEU/status/927548668722470912
https://twitter.com/medicinesforEU/status/927547492488622080